# Addiction Medicine Consultation

> **SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD**

- Patient: Calamity Jane (real historical name used in a fictional teaching record)
- Synthetic MRN: HR-NI008-SYN-TD
- Date: 1901-03-09
- Fictional facility: St. Posthumous Health Center
- Fictional author: Dolores Two Bulls-Harmon, MD
- Calendar frame: true historical dates (modern content is anachronistic)

> True-date frame: synthetic events are moved into the patient's historical lifetime. Codes, instruments, and treatments remain modern and are anachronistic.

- Requested by: Ruth Ann Kessler, MD

## Reason for consultation

Severe alcohol use disorder in a 44-year-old woman without stable housing, starting outpatient withdrawal management today. Please confirm the diagnosis, review the withdrawal plan and advise on a medicine for alcohol use disorder, her liver, her mood and recovery support. **S**

## History

Ms. Canary, a 44-year-old woman who does odd jobs and moves between towns, is seen at the request of Dr. Kessler one week after starting outpatient withdrawal management. She has drunk heavily for most of her adult life and has tried to stop many times on her own. Her last drink was a week ago. With gabapentin, thiamine and daily nurse checks, her withdrawal peaked at a CIWA-Ar of 10 on the second day and is now over. She wants to stop drinking altogether, does not want to be lectured, and would rather not take a pill every day if there is another way. She has a friend who supports her and has met the clinic's peer recovery specialist. **S**

## Examination

| System | Finding |
|---|---|
| General | Alert; blood pressure 128/82, pulse 84 |
| Eyes | No nystagmus; no scleral icterus |
| Neurological | No tremor; gait steady; oriented |
| Abdomen | Soft and non-tender; liver edge not palpable |

BP 128/82 mmHg; pulse 84 bpm; respirations 16/min; temperature 36.8 °C; oxygen saturation 98% on room air; weight 50.4 kg; BMI 18.5 kg/m². All vital signs are synthetic.

## Data reviewed

Dr. Kessler's intake note and safety assessment; the nurse's daily CIWA-Ar scores (10 at most, 2 today). AUDIT 31, PEth 820 ng/mL, PHQ-9 14, GAD-7 11 and PC-PTSD-5 2 at intake. Intake laboratory results: AST 96, ALT 44 and GGT 240 U/L, albumin 3.4 g/dL, bilirubin 1.1 mg/dL, INR 1.0, platelets 162, MCV 103 fL; FIB-4 3.93. Today potassium 3.9 mmol/L and magnesium 1.8 mg/dL after replacement. HIV and hepatitis C negative; hepatitis B not infected and not immune; urine drug test negative for opioids, fentanyl and other drugs; pregnancy test negative. Potassium: 3.9 mmol/L; Magnesium: 1.8 mg/dL. All results are synthetic.

## Assessment

1. **Severe alcohol use disorder** (F10.20). Nine DSM-5-TR criteria, including craving, failed attempts to cut down, use despite harm to her health and her work, tolerance and withdrawal: a severe disorder. Her long drinking began in a childhood of loss and poverty, and it is met here with treatment, not blame. **S**
2. **Alcohol withdrawal** (F10.230). With a PAWSS of 3, no past seizures or delirium, a support person and daily checks, ambulatory management was appropriate under the ASAM guideline, and gabapentin was a reasonable choice for mild withdrawal in a woman likely to be alone at times and with raised liver tests. Withdrawal is now complete. **S**
3. **Medicine for alcohol use disorder** (F10.20). Naltrexone is a first-line choice under the APA guideline and suits her goal of stopping. Her AST is under three times the upper limit and she has no signs of cirrhosis or hepatitis, so it can be used with liver tests rechecked. The monthly extended-release injection removes the need for a daily pill and suits a woman who moves between places. Acamprosate is the alternative if naltrexone cannot be used; disulfiram is not advised with her liver tests and without someone to supervise doses. She takes no opioids, and the urine test confirms it. **S**
4. **Raised liver enzymes with a high FIB-4** (R74.01). An AST twice the ALT with a high GGT and macrocytosis fits alcohol-associated liver injury. A FIB-4 above 2.67 needs transient elastography; done after a few weeks without alcohol, it is less likely to be falsely raised by inflammation. Bilirubin, albumin, INR and platelets show no sign of liver failure. **S**
5. **Depressive symptoms during heavy drinking** (F32.A). Depressive symptoms during heavy drinking often improve within two to four weeks of stopping. With no suicidal thoughts and a safety plan in place, reassessment with the PHQ-9 at about four weeks is reasonable before deciding on an antidepressant. **S**
6. **Recovery, harm reduction and social needs**. Recovery is likelier with housing, food and someone to call. Peer support and a mutual-help group of her choice, including women-only options, help many women. Women develop liver damage after less drinking and fewer years than men, and alcohol raises breast cancer risk; she should hear this plainly. A plan for a return to drinking keeps her safe and in care. **S**

## Recommendations

1. Start naltrexone 50 mg daily now; change to extended-release naltrexone 380 mg intramuscularly every four weeks if daily tablets are hard to keep.
2. Recheck liver enzymes at about four weeks and then periodically; stop naltrexone for symptoms of hepatitis.
3. Give her a wallet card stating that naltrexone blocks opioids; treat pain with non-opioid medicines.
4. Transient elastography at about four weeks without alcohol, and again after several months; hepatitis A and B vaccination.
5. PHQ-9 and GAD-7 at four weeks; an antidepressant only if symptoms persist after a month or more without alcohol.
6. PEth at about four weeks and every one to two months, explained as part of care.
7. Weekly peer recovery contact and a mutual-help group of her choice (Alcoholics Anonymous, SMART Recovery or Women for Sobriety).
8. A written plan for a return to drinking: call the peer specialist or the clinic, eat, do not drink alone or drive, keep taking naltrexone, and come back without shame.
9. Continue thiamine 100 mg and folic acid 1 mg daily.
10. Medicaid, SNAP, a food bank and the local housing program through the community health worker.

## Strengths and supports

- Engagement in care and meaningful activity **S**

## Communication

Discussed with Dr. Kessler, who saw her the same day. The options were explained to Ms. Canary in plain words; she chose to start naltrexone tablets and to consider the monthly injection. **S**

## Follow-up

Dr. Kessler continues prescribing and the monthly reviews; addiction medicine will see her again if she returns to drinking for more than a few days, cannot use naltrexone, or wants to discuss another medicine. **S**

## Guideline basis

- The American Psychiatric Association Practice Guideline for the Pharmacological Treatment of Patients With Alcohol Use Disorder (2018), American Psychiatric Association (American Journal of Psychiatry 2018;175(1):86-90)
- The ASAM Clinical Practice Guideline on Alcohol Withdrawal Management (2020), American Society of Addiction Medicine (Journal of Addiction Medicine 2020;14(3S Suppl 1):1-72)
- The Healthcare Professional's Core Resource on Alcohol (2026), National Institute on Alcohol Abuse and Alcoholism
- Diagnosis and Treatment of Alcohol-Associated Liver Diseases: 2019 Practice Guidance From the American Association for the Study of Liver Diseases (2019), American Association for the Study of Liver Diseases (Hepatology 2020;71(1):306-333)
- CMID: Clinical Monitoring Intelligence Database, depression, bipolar, and mood disorders monograph (2026), Aether Forge
